Funder
Institut de Recherche Pierre Fabre
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Bitter I, Lieberman JA, Gaudoux F, Sokoloff P, Groc M, Chavda R et al (2019) Randomized, double-blind, placebo-controlled study of F17464, a preferential D3-antagonist, in the treatment of acute exacerbation of schizophrenia. Neuropsychopharmacology 44(11):1917–1924
2. Breden EL, Liu MT, Dean SR (2009) Metabolic and cardiacs side effects of second-generation antipsychotics: What every clinician should know. J Pharm Pract 22:478–488
3. Conley RR, Kelly DL (2005) Second generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. J Psychiatr Relat Sci 42:51–60
4. Fusar-Poli PF, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, McGuire P (2015) Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull 41(4):892–899
5. Gallezot JD, Beaver JD, Gunn RN, Nabulsi N, Weinzimmer D, Singhal T, Slifstein M, Fowles K, Ding YS, Huang Y, Laruelle M, Carson RE, Rabiner EA (2012) Affinity and selectivity of [(1)(1)C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. Synapse 66(6):489–500
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献